Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIIS-CPA study of isavuconazonium sulfate in Japanese patients with chronic pulmonary aspergillosis
jRCTs071230121Recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of isavuconazonium in chronic pulmonary aspergillosis (CPA), sponsored by Asahi Kasei Corporation. Primary endpoints: Adverse event incidence, Adverse reaction incidence and 4 more. Started May 2024; status: recruiting.
02
Drugs
isavuconazonium
03
Conditions
chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on jRCTs071230121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230121.